Biomarin Pharmaceutical vs Neurocrine Biosciences
Biomarin Pharmaceutical and Neurocrine Biosciences are similar in size: $3.22bn and $2.86bn of revenue in their latest fiscal years. Neurocrine Biosciences grew faster (21.4% against 12.9%). Neurocrine Biosciences kept more of each dollar of sales as profit: a net margin of 16.7% against 10.8%. Neurocrine Biosciences carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | Biomarin PharmaceuticalBMRN, 2025 | Neurocrine BiosciencesNBIX, 2025 |
|---|---|---|
| Revenue | $3.22bn | $2.86bn |
| Revenue growth | 12.9% | 21.4% |
| Net income | $349m | $479m |
| Operating margin | 12.7% | 21.6% |
| Net margin | 10.8% | 16.7% |
| Return on equity | 5.9% | 16.4% |
| Free cash flow | $725m | $749m |
| Cash | $1.31bn | $713m |
| Total debt | $600m | $0 |
| Debt to equity | 9.9% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $168m |
| Employees | 3,221 | 1,800 |
| Market value | $10.80bn | $16.93bn |
| Price vs our value range | Within our value range | Below our value range |
| Moat score | 40 (Weak) | 61 (Moderate) |
| Insider trades, 12 months | 0 buys, 5 sales | 0 buys, 40 sales |